NASDAQ:QSI Quantum-Si Q3 2023 Earnings Report $1.15 -0.01 (-0.86%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.14 -0.01 (-1.30%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Quantum-Si EPS ResultsActual EPS-$0.15Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AQuantum-Si Revenue ResultsActual Revenue$0.22 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuantum-Si Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call DateThursday, November 9, 2023Conference Call Time4:30PM ETUpcoming EarningsQuantum-Si's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Quantum-Si Q3 2023 Earnings Call TranscriptProvided by QuartrNovember 9, 2023 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Good day and thank you for standing by. Welcome to the Quantum Mass IQ 3 2023 Earnings Call. Will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please be advised that today's conference is being recorded. Operator00:00:32I would now like to hand the conference over to your speaker today, Kathryn Atkinson. Please go ahead. Speaker 100:00:44Ready to begin. Good afternoon, everyone. Thank you for joining us. Earlier today, Quantum SI released financial results for the Q3 ended September 30, 2023. A copy of the press release is available on the company's website. Speaker 100:00:57Joining me today are Jeff Hawkins, President and Chief Executive Officer and Jeff Kides, Chief Financial Officer. Before we begin, I would like to remind you that management will be making certain forward looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to incurially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward Looking Statements of our press release. For a more complete list and description of risk factors, please see the company's filings made with the Securities and Exchange Commission. Speaker 100:01:35This conference call contains time sensitive information that is accurate only as of the live broadcast today, November 9, 2023. Except as required by law, the company disclaims any intention or obligation to update or revise any forward looking statements. During this call, we will also be referring to certain financial measures that are not prepared in accordance with the U. S. Generally Accepted Accounting Principles or GAAP. Speaker 100:02:00A reconciliation of these non GAAP financial measures to the most directly comparable GAAP financial measures is included in the press release filed earlier today. Begin. With that, I will turn the call over to Jeff Hawkins. Speaker 200:02:13Thank you, Catherine. Good afternoon, everyone, and thank you for joining us. In today's call, we will provide a business update, present our Q3 financial performance and provide an outlook for the remainder of 2023. We will then open the line for questions. As you are aware, the goal of Quantum SI is to bring next generation protein sequencing to every lab, everywhere. Speaker 200:02:35Our proprietary technology delivers deeper unbiased proteomics insights that we believe will accelerate scientific research, enable the discovery of new biomarkers and ultimately power the development of new therapies and diagnostic tests that will positively impact human health. Before sharing updates on our progress during the quarter, I wanted to take an opportunity to look back on the significant progress that we have made as a company during my 1st year as CEO. First, we have enhanced the leadership team with the addition of proven industry leaders across key roles, including our Chief Financial Officer, Chief Commercial Officer, Senior Vice President of Operations and Senior Vice President of Product Development. 2nd, we commercially launched Platinum, the world's 1st next generation protein sequencing platform. 3rd, we have augmented our Board of Directors through the addition of 3 new independent directors, all with CEO or CFO experience from across life sciences, medical devices, diagnostics and biotech. Speaker 200:03:42In addition, we established an independent chair of our nominating and governance committee as we strive to continually improve our Board governance and performance. 4th, we have completely retooled our reagent and consumable manufacturing model from one that was largely outsourced to one that is majority insourced. This has provided us with greater control over quality and cost production should result in improved gross margins as we achieve scale. Finally, we have completed a reorganization of our R and D team and focused our R and D projects on the capabilities and applications customers want most. We have shifted a greater percentage of our investments into near to mid term opportunities, while retaining a focused investment into a compelling set of next generation technologies. Speaker 200:04:30Overall, the progress over the past 12 months has fundamentally improved all aspects of our business, putting us on a strong foundation for growth in 2024 and beyond. I would now like to provide an update on our progress during the quarter. Our first corporate priority is to commercialize Platinum and the 2 ms chip. Our sales funnel continues to grow and remains well ahead of our expectations for 2023. Quantum SI's technology addresses gaps in currently marketed technologies and it is clear customers are interested in using platinum in their research. Speaker 200:05:05From a geographic standpoint, we continue to see interest across both the United States and Europe. During the quarter, We participated in the Hoopo World Congress in Busan, South Korea. This event gave us our first opportunity to meet with potential customers and distributors in the Asia Pacific region. The team came back from this event energized about the opportunity to launch Platinum in the Asia Pacific region in 2024. In October, the first customer data using PLATINUM was presented during a webinar. Speaker 200:05:38Doctor. Tolman Erskic from Northwestern University leads a lab that focuses on protein engineering, spanning both therapeutic and industrial applications. During the webinar, she discussed some of the methods they use for characterizing engineered proteins in our lab and she presented data generated on platinum that was used for studying secreted protein variants. She also talked about how they plan to use platinum for other protein engineering applications such as barcoding and selecting for genotype, phenotype linkage in proteins. Beyond the specific applications of interest, the webinar also included discussion of the overall time savings of platinum workflow that the lab has experienced. Speaker 200:06:19As we look out across the remainder of 2023, we expect the 1st customer generated manuscript will also be submitted for publication. We are excited about the momentum we are building in the market and believe it will position us well as we move from our current controlled commercial launch to full commercial launch in early 2024. Our second priority is to lead with innovation. During the quarter, we completed the strategic review of our research and development programs and our organizational design and capacity that we had discussed on our last call. I would like to share some key outcomes from this process. Speaker 200:06:57First, we reorganized the team to drive greater focus in product development. Post the organizational changes, we now have more than 60% of our team deployed against near to mid term opportunities. We believe this change will allow us to more rapidly deliver the technology capabilities and applications customers want most. As part of the reorganization, we are accelerating our efforts in biochemistry to further build upon our industry leading Next generation protein sequencing technology capabilities. We are already seeing positive early signs from this renewed focus are confident that it will yield strong results in 2024 and beyond. Speaker 200:07:37Finally, we have retained a focus set of investments in next generation technologies to ensure we remain on the path to being the 1st company to deliver de novo sequencing in the future. Another goal of the R and D strategic review was to evaluate all of our projects and define a more focused and prioritized set of initiatives. As part of that process and consistent with our prior earnings call, we completed a review of the carbon program. After a comprehensive review of the carbon program, we have determined that we will not move forward with commercialization of the carbon instrument at this time. It was clear from our discussions with customers that Carbon was not required for successful implementation of platform and that there were higher impact R and D programs we could work on to advance our customers' research. Speaker 200:08:28To that end, during the strategic review process, we identified several product improvements across our library prep kit, sequencing reagents and chips that could improve the sequencing output per sample, coverage and overall robustness of the full workflow from library prep to sequencing results. I am pleased to share that these improvements will be included in a version 2 of our kits, which we expect to launch in the Q1 of 2024. We expect that these improvements will also provide greater compatibility between our next generation protein sequencing technology and the range of sample prep methods, sample types and even specific proteins our customers are interested in studying. Overall, we believe that the Version 2 kit combined with the work we are doing around sample prep compatibility puts us on a strong path towards full commercial launch in early 2024. Given this, We have initiated a set of commercial activities to ensure we are well prepared for that event. Speaker 200:09:31While we are still in the early days of operating in this new structure and projects are focused on R and D projects. I am optimistic that we are well positioned to deliver a steady cadence of new technology capabilities and applications throughout 2024. Our 3rd priority is to preserve financial strength. Capital we have been provided is utilized to maximize shareholder value and our financial runway. Given our efforts to date and our commitment to continuous improvement, we remain confident that our current capital can support operations into 2026. Speaker 200:10:13I will now turn the call over to Jeff Keis will review our financial results. Jeff? Speaker 300:10:21Thank you, Jeff. Now let's discuss the details of our Q3 2023 financial results. Revenue in the Q3 of 2023 was $223,000 which consisted of revenue from our platinum instrument and associated consumable kits. Gross profit was $108,000 Speaker 400:10:41and the Speaker 300:10:41gross margin was 48%. As I have stated before, our gross margin percentage will be somewhat variable for the near future as we work through our initial stages of commercialization and will also be impacted by the timing and mix of instruments versus consumable sales. GAAP total operating expenses in the Q3 of 2023 were $27,300,000 compared to 27,700,000 in the Q3 of 2022. Included within operating expenses are stock based compensation and restructuring charges. Removing these items, we arrive at an adjusted operating expenses, which were $23,900,000 for the Q3 of 2023 compared to $23,600,000 for the Q3 of 2022, reflecting an approximate $300,000 increase. Speaker 300:11:34What's important here is the details of the change. As a company, we have been able to maintain a minimal increase to our adjusted total operating expenses year over year for the quarter, while at the same time, we have ramped up our commercial operations team significantly. We have been able to do this based on our recent R and D realignment efforts as well as our disciplined efforts to utilize our capital in the most effective ways as possible. This is further displayed with our year over year adjusted total operating expenses. For the year to date period September 2023, adjusted total operating expenses is $72,600,000 compared to 77,900,000 for the same period in 2022, a $5,300,000 decrease. Speaker 300:12:21Though we are not committing to a particular operating expense spend level at this time, We are very aggressively looking at our spend to ensure maximum utilization of our capital to enhance and speed our R and D results, While ensuring that we have the resources to maximize our market penetration with our commercial team. Net loss for the Q3 of 2023 was $24,700,000 compared to $31,700,000 in the Q3 of 2022 and adjusted EBITDA for the Q3 of 2023 was negative $22,600,000 compared to negative $22,900,000 in the Q3 of 2022. As of September 30, 2023, we had $274,600,000 of cash, cash equivalents and investments in marketable securities. As we discussed today and previously, our guidance for the rest of 2023 includes our controlled commercial launch approach, while continuing to put in place significant building blocks from a commercial capability standpoint for execution for an anticipated full commercial launch in early 2024. Based on our R and D realignment progress and other initiatives, We expect our adjusted total operating expenses to be $100,000,000 for 2023 compared to $103,200,000 in 2022. Speaker 300:13:47We are still very confident that our existing cash, cash equivalents and investments in marketable securities will provide runway into 2026. Now I will turn the call back over to Jeff Hawkins for closing remarks. Speaker 200:14:03Thank you, Jeff. We have made significant progress during the last quarter led by the completion of our R and D strategic review. We are excited about the level of clarity and focus we achieved through this process, including the roadmap to deliver near and midterm product improvements, including our anticipated version 2 of our kits on track for launch in the Q1 of 2024. We are looking forward to providing additional updates on the version 2 will be participating in the next call. In the meantime, we are continuing to build our infrastructure to support our full commercial launch, are well adhering to our disciplined approach to capital deployment. Speaker 200:14:39Operator, please open the line for questions. Speaker 400:14:59Will be ready for questions. Operator00:15:01And your first question comes from the line of Kyle Mixon with Canaccord Genuity. Your line is now open. Speaker 400:15:09Hey, guys. Thanks for taking the questions. Jeff, I know you guys have this controlled launch ongoing and we shouldn't expect A huge uptick or bolus in placement anytime soon, I guess, and that makes sense, relatively appropriate given like the early stage of this launch. But it seems like a couple of placements again this quarter. How should we think about the placement and the shipment like trajectory kind of going forward? Speaker 400:15:36Is this controlled truly going to be kind of a couple of places each quarter or how should we start to think about it in the near term release and maybe going into 2024? Speaker 200:15:44Yes. Thanks for that question, Kyle. So I would say 2 things about it. I think we're in that controlled launch through the end of this year. As part of our preparation for a full launch early next year, we are initiating some commercial activities Both in terms of some hiring and potentially distribution related partners. Speaker 200:16:08So you may see a little uptick In the Q4 over what we've done the last couple of quarters, but not a sort of a significant rise. Really then the focus becomes the V2 kit launch in the Q1. And we really believe that's the catalyst. That kit in the hands of customers And seeing that increased performance become sort of the catalyst to be able to move to a full launch and start to see a scale up sort of quarter over quarter after that. Speaker 400:16:40Okay. All right. That was great. And then I guess most of the revenue right now is coming from instruments. That's probably some service revenue. Speaker 400:16:47That's relatively lower margin than consumables and this new kit sounds like that will help drive utilization next year and thereafter. But 45% and kind of like the high 40s, I think is what gross margin has been at thus far. Obviously pretty good for if your revenue base is instrument and service. So as you sort of roll out These improved kits and you have the utilization picking up with the expanding installed base. Could we see gross margin get above 50% next year at some point? Speaker 200:17:18Yes. Maybe I'll start and then I'll turn it over to Jeff for a few comments. The one thing I wanted to input here, Kyle, was As we've talked about on other calls, we did do a tremendous amount of value engineering when we built our machine. While we are selling an instrument in selling capital and there's sort of perceived margins of selling that, Obviously, at a much earlier stage, but maybe Jeff wants to comment a little bit on how we are thinking about that blend and sort of how it might change over the course of next year. Speaker 300:17:58Yes. I'll just add on saying that as we scale, we're going to have more opportunities to bring more and more of the kit manufacturing in house And have the ability to improve margins on that. Obviously, we need that scale to be able to achieve that improvement, But it's absolutely on our radar as we ramp up over the course of 2024 and beyond. Speaker 400:18:21Okay. That was great. That was great, guys. And Jeff Hawkins, is there anything you could kind of share with respect to the Almost like the backlog of customers and kind of like the leads that you've generated thus far and things like types of customers, The end markets, I know we talked about biotech before and maybe even like regions because there's a lot to think about when you think about the backlog and kind of pipeline. So it would be good to hear like what Be excited for going forward. Speaker 200:18:49Sure. Yes. The first thing I'd say Kyle is that the funnel tends to be sort of consistent with what we said in the in the quarter, it's heaviest in the U. S. Where we have our direct presence, still have a strong amount sort of similar levels to Q2 In terms of funnel in Europe, by coming out of the Hoopo World Congress, as we mentioned in our prepared remarks, Starting to get some of our first leads into the funnel for the Asia Pacific region. Speaker 200:19:20So I think as we get more visibility into Those other markets and interface with both customers and distributors will start to pick up in that regard. In terms of The split the academic market remains the biggest portion of our funnel. But as we said earlier in the year, we expected that Academic customers would represent those first customers in the majority of the funnel and then we would work and over time, We'd see it start to build in the pharma, biotech, and even government and industrial space. And I think that's what's transpiring. So the funnel continues to be over weighted to academic, but we are seeing more traction and we're getting sort of further into The funnel and the process with some of the pharma biotechs and government sort of accounts. Speaker 200:20:08So excited to see those types of customers Progressing, obviously, those types of customers can be very helpful in terms of your pull through And such, so excited about that trend as we look out to 2024. Speaker 400:20:25Okay. And then is anyone in the current installed base like a non beta user? Because I figure like most of these handful Of placements out there in the field are probably with those initial early access program users. And then with the funnel, I mean, that could be many potential placements over time. How many like new to QSI or new to, proteomics possibly customers does that represent? Speaker 200:20:51So our current installed base is Almost all are new to QSI. They were not necessarily part of the early access program. So the vast majority of those placements we've made throughout the year, Kyle, are net new to us in terms of not having been a part of the early access Program. Speaker 400:21:17Yes. Okay. That's great. That's great. Let me just ask another one, a last one before I hop off. Speaker 400:21:22On the pipeline and possibly the kits and everything, so you talked about how carbon is going to be, I guess, Discontinued, you're not going to be commercializing that anymore. In your explanation, it makes sense. I know it was touched on last quarter as well. And it sounds like that was kind In the cards, I guess, so it's not super surprising. As you look forward though, I mean, what type of hardware updates Or improvements do you sort of envision for Quantum SI? Speaker 400:21:47Like could there be a new box anytime soon? Is that necessary Maybe to get I feel like in Proteomics, there are some of these attributes and features that have to be kind of pretty robust and that does require I got a legitimate hardware type upgrade rather than just reagents, but that's one side of the question. The other is the version 2 kits and then we'll hear more about those. Is that mainly around Like increasing density of the chips or is this completely new, just chemistry based or something like that? Speaker 200:22:14Sure. Yes, let's take the 2 questions. So in terms of hardware versus kits, I would say that there's The existing platinum instrument and the existing 2 ms chip have a lot of headroom in terms of their capabilities and performance. The majority of what we need to do right now to unlock that is around a combination of the library prep, The sequencing reagent kit and even somewhat the surface chemistry of the chip that can influence things like loading. A lot of the focus is there. Speaker 200:22:51We certainly are working through our plans as it relates to what New types of hardware we might want to introduce over the coming years. We haven't really set a firm date on what the next platform would be, But we do see opportunities to continue to sort of grow the hardware portfolio to address other attributes that platform doesn't necessarily address today. I mean, in terms of the Version 2 kit, Kyle, the way I would think about it is We are touching upon improvements sort of across the set of kits that we sell to a customer. Everything from enhancements to the library prep kit and protocol, enhancements to the sequencing Reagents including the addition of a new recognizer for glutamic acid or E And just for your reference, right, that's the 3rd most abundant amino acid in the proteome. And then just overall increasing Through some improvements to surface chemistry, the sort of the amount of reads, the amount of output we're getting per run on the current chip. Speaker 200:24:02So, we expect to have more quantitative data to share when we get to the launch in the Q1 of next year. But Early data here internally in development, really market improvement over The current version of the chemistry and also seeing a lot lower sort of sample input requirement with the new library prep Sort of kit and protocol, which should help us really with that compatibility with the various sample prep kits and sample types. So we think that might improve Some of those interfaces with what the customer is trying to do upfront of our kits. Speaker 400:24:44Okay. Yes, sounds like a pretty solid and comprehensive update. I look forward to that. Thanks guys. Appreciate the time. Speaker 200:24:49Yes. Thank you, Kyle. Operator00:24:54One moment for the next question. And your next question comes from the line of Swayampakula Ramakanth with HCW. Your line is now open. Speaker 500:25:07Thank you. Good afternoon, Jeff and Jeff. Speaker 200:25:10Hi, Arnaud. Good afternoon. Operator00:25:14So Speaker 500:25:17You are planning to initiate the full launch early next year And at the same time also launch a second version of the kit. I'm just trying to understand Is there any reason for us to think one would happen before the other? Are they going to happen Together and are they dependent on each other in terms of deployment? I'm just trying to understand if there's What is the sequence of events that Reshinde is looking out for? Speaker 200:25:59Yes. RK, I would say that the working plan is that we would launch the V2 kit and then at Some period of time shortly after that, we would move to the full launch. I would not expect us to move to full launch in advance Of the V2 kit, we would sort of stay in the controlled launch we're in right now. So that's the way I would think about it as V2 kit And then somewhere between right after that to just shortly after that, we would move to the full launch. Speaker 500:26:31Okay. And what I don't I guess you'll discuss the V2 later. But in general terms, Is this going to be anything significantly different or in the sense that you need additional tweaking to the machine as it is now? Or do you you don't think there is something majorly different in the kit itself? Yes. Speaker 500:26:55So the machine Speaker 200:26:57is not impacted by this at all. The version 2 kits will be compatible with the existing platinum instrument that customers have. This is really improvements to a mix of either the library prep or sequencing reagents or an improvement we've made To the chip, we're not fundamentally changing the underlying 2 ms chip or the hardware itself. It's really this will be very seamless For customers, they'll receive the library prep and sequencing kits and run them with the same instrument and the same software they've been using It'd be a fairly seamless change for them. No sort of specific upgrades they need to go through. Speaker 500:27:36Okay. And then in terms of the data presentations or data publications that you're expecting this year and early next year. What sort of data should we be expecting from it? And then, would that data pretty much Portray what the current version of the instrument can deliver? Or is this going to be Something a little bit more than that in the sense so people like us can kind of think about, okay, what the next The version of the instrument itself could be and what better capabilities can be delivered? Speaker 200:28:20Sure. We talked about in the script the webinar and the presentation from Northwestern. That really represents the performance That customers are generating today with the existing instrument and the existing version of the chemistry. The publication that we discussed that we expect to be submitted before the end of the year, really showing some of the capabilities of the technology in the world of post translational modifications, but again using the existing kit and instrument. As we get into next year, I'd expect in the beginning of the year that any data that comes out would be generated with the kits that are in the market right now. Speaker 200:29:04And as the year progresses, more and more of that data coming out with the Version 2 kits. So there's always some lag between A version of chemistry and data that gets generated with that. But that's sort of how I would think about the near term versus midterm and throughout 2024. Speaker 500:29:23Okay, perfect. Yes. So basically those publications can certainly be used in marketing the products that are in the market right now. Speaker 200:29:32Yes, they could be used for that. We will obviously share internal data as part of our launch of the Version 2 kit to sort of prime But then turning immediately to working with some of these existing customers that have been part of the controlled launch Quickly implement the V2 in their laboratories and generate some data with that. So, you'll get a little bit more of a running start When you have an existing installed base, when you bring in an upgraded chemistry like we're going to do. Speaker 500:30:06Okay. And then you were talking about the ex U. S. Launch. With the way the launch is going here in the U. Speaker 500:30:16On a limited control basis, is the ex U. S. Launch It's going to be more like a typical launch or is that because it's going to be through a distributorship That it should be viewed a little bit different than what it is what is happening here in the United States. Speaker 200:30:42It's a good question, RK. So the way I think about it is, again, the Version 2 kit we think is really A key aspect of giving us the type of consistency of performance and capabilities that Make the implementation and adoption a sort of cycle with the customer as efficient as possible. That said, when we look at Europe, while we expect to have a small number of employees on the ground there to help support our activities. We do expect to use distributors in many markets. We haven't decided exactly Which markets, we may go direct in select markets, but I would expect us to use a reasonable number of countries being covered by distributors. Speaker 200:31:31I think our experience in markets like Europe would say that in the beginning, there'll be some Of that early market development, right, instrument being placed with the KOL, data being generated, being presented or At a major conference in the region, or being coming that sort of reference account and then you'll see sort of the sales pick up. So I don't expect The European launch to necessarily be in a defined sort of controlled launch. I would expect it to be more of a traditional launch, but with that initial Market development that exists when you place an instrument either directly or with a distributor in a new region of the world. Speaker 500:32:14Okay, Perfect. Thank you. Thank you for taking all my questions. Speaker 200:32:18You're welcome. Operator00:32:21And that is Speaker 200:32:29Thank you everyone for attending today. We look forward to providing you with more updates on our next call. Have a good evening.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallQuantum-Si Q3 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Quantum-Si Earnings HeadlinesQuantum-Si (NasdaqGM:QSI) Launches Platinum Pro Amid 5% Stock Dip Over The Past MonthApril 3, 2025 | finance.yahoo.comQuantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™March 26, 2025 | finance.yahoo.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 19, 2025 | Crypto Swap Profits (Ad)Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics ResearchMarch 24, 2025 | businesswire.comQuantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 13, 2025 | businesswire.comQuantum-Si: Still Unproven, Investors BewareMarch 12, 2025 | seekingalpha.comSee More Quantum-Si Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum-Si? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum-Si and other key companies, straight to your email. Email Address About Quantum-SiQuantum-Si (NASDAQ:QSI), a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.View Quantum-Si ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Good day and thank you for standing by. Welcome to the Quantum Mass IQ 3 2023 Earnings Call. Will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please be advised that today's conference is being recorded. Operator00:00:32I would now like to hand the conference over to your speaker today, Kathryn Atkinson. Please go ahead. Speaker 100:00:44Ready to begin. Good afternoon, everyone. Thank you for joining us. Earlier today, Quantum SI released financial results for the Q3 ended September 30, 2023. A copy of the press release is available on the company's website. Speaker 100:00:57Joining me today are Jeff Hawkins, President and Chief Executive Officer and Jeff Kides, Chief Financial Officer. Before we begin, I would like to remind you that management will be making certain forward looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to incurially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward Looking Statements of our press release. For a more complete list and description of risk factors, please see the company's filings made with the Securities and Exchange Commission. Speaker 100:01:35This conference call contains time sensitive information that is accurate only as of the live broadcast today, November 9, 2023. Except as required by law, the company disclaims any intention or obligation to update or revise any forward looking statements. During this call, we will also be referring to certain financial measures that are not prepared in accordance with the U. S. Generally Accepted Accounting Principles or GAAP. Speaker 100:02:00A reconciliation of these non GAAP financial measures to the most directly comparable GAAP financial measures is included in the press release filed earlier today. Begin. With that, I will turn the call over to Jeff Hawkins. Speaker 200:02:13Thank you, Catherine. Good afternoon, everyone, and thank you for joining us. In today's call, we will provide a business update, present our Q3 financial performance and provide an outlook for the remainder of 2023. We will then open the line for questions. As you are aware, the goal of Quantum SI is to bring next generation protein sequencing to every lab, everywhere. Speaker 200:02:35Our proprietary technology delivers deeper unbiased proteomics insights that we believe will accelerate scientific research, enable the discovery of new biomarkers and ultimately power the development of new therapies and diagnostic tests that will positively impact human health. Before sharing updates on our progress during the quarter, I wanted to take an opportunity to look back on the significant progress that we have made as a company during my 1st year as CEO. First, we have enhanced the leadership team with the addition of proven industry leaders across key roles, including our Chief Financial Officer, Chief Commercial Officer, Senior Vice President of Operations and Senior Vice President of Product Development. 2nd, we commercially launched Platinum, the world's 1st next generation protein sequencing platform. 3rd, we have augmented our Board of Directors through the addition of 3 new independent directors, all with CEO or CFO experience from across life sciences, medical devices, diagnostics and biotech. Speaker 200:03:42In addition, we established an independent chair of our nominating and governance committee as we strive to continually improve our Board governance and performance. 4th, we have completely retooled our reagent and consumable manufacturing model from one that was largely outsourced to one that is majority insourced. This has provided us with greater control over quality and cost production should result in improved gross margins as we achieve scale. Finally, we have completed a reorganization of our R and D team and focused our R and D projects on the capabilities and applications customers want most. We have shifted a greater percentage of our investments into near to mid term opportunities, while retaining a focused investment into a compelling set of next generation technologies. Speaker 200:04:30Overall, the progress over the past 12 months has fundamentally improved all aspects of our business, putting us on a strong foundation for growth in 2024 and beyond. I would now like to provide an update on our progress during the quarter. Our first corporate priority is to commercialize Platinum and the 2 ms chip. Our sales funnel continues to grow and remains well ahead of our expectations for 2023. Quantum SI's technology addresses gaps in currently marketed technologies and it is clear customers are interested in using platinum in their research. Speaker 200:05:05From a geographic standpoint, we continue to see interest across both the United States and Europe. During the quarter, We participated in the Hoopo World Congress in Busan, South Korea. This event gave us our first opportunity to meet with potential customers and distributors in the Asia Pacific region. The team came back from this event energized about the opportunity to launch Platinum in the Asia Pacific region in 2024. In October, the first customer data using PLATINUM was presented during a webinar. Speaker 200:05:38Doctor. Tolman Erskic from Northwestern University leads a lab that focuses on protein engineering, spanning both therapeutic and industrial applications. During the webinar, she discussed some of the methods they use for characterizing engineered proteins in our lab and she presented data generated on platinum that was used for studying secreted protein variants. She also talked about how they plan to use platinum for other protein engineering applications such as barcoding and selecting for genotype, phenotype linkage in proteins. Beyond the specific applications of interest, the webinar also included discussion of the overall time savings of platinum workflow that the lab has experienced. Speaker 200:06:19As we look out across the remainder of 2023, we expect the 1st customer generated manuscript will also be submitted for publication. We are excited about the momentum we are building in the market and believe it will position us well as we move from our current controlled commercial launch to full commercial launch in early 2024. Our second priority is to lead with innovation. During the quarter, we completed the strategic review of our research and development programs and our organizational design and capacity that we had discussed on our last call. I would like to share some key outcomes from this process. Speaker 200:06:57First, we reorganized the team to drive greater focus in product development. Post the organizational changes, we now have more than 60% of our team deployed against near to mid term opportunities. We believe this change will allow us to more rapidly deliver the technology capabilities and applications customers want most. As part of the reorganization, we are accelerating our efforts in biochemistry to further build upon our industry leading Next generation protein sequencing technology capabilities. We are already seeing positive early signs from this renewed focus are confident that it will yield strong results in 2024 and beyond. Speaker 200:07:37Finally, we have retained a focus set of investments in next generation technologies to ensure we remain on the path to being the 1st company to deliver de novo sequencing in the future. Another goal of the R and D strategic review was to evaluate all of our projects and define a more focused and prioritized set of initiatives. As part of that process and consistent with our prior earnings call, we completed a review of the carbon program. After a comprehensive review of the carbon program, we have determined that we will not move forward with commercialization of the carbon instrument at this time. It was clear from our discussions with customers that Carbon was not required for successful implementation of platform and that there were higher impact R and D programs we could work on to advance our customers' research. Speaker 200:08:28To that end, during the strategic review process, we identified several product improvements across our library prep kit, sequencing reagents and chips that could improve the sequencing output per sample, coverage and overall robustness of the full workflow from library prep to sequencing results. I am pleased to share that these improvements will be included in a version 2 of our kits, which we expect to launch in the Q1 of 2024. We expect that these improvements will also provide greater compatibility between our next generation protein sequencing technology and the range of sample prep methods, sample types and even specific proteins our customers are interested in studying. Overall, we believe that the Version 2 kit combined with the work we are doing around sample prep compatibility puts us on a strong path towards full commercial launch in early 2024. Given this, We have initiated a set of commercial activities to ensure we are well prepared for that event. Speaker 200:09:31While we are still in the early days of operating in this new structure and projects are focused on R and D projects. I am optimistic that we are well positioned to deliver a steady cadence of new technology capabilities and applications throughout 2024. Our 3rd priority is to preserve financial strength. Capital we have been provided is utilized to maximize shareholder value and our financial runway. Given our efforts to date and our commitment to continuous improvement, we remain confident that our current capital can support operations into 2026. Speaker 200:10:13I will now turn the call over to Jeff Keis will review our financial results. Jeff? Speaker 300:10:21Thank you, Jeff. Now let's discuss the details of our Q3 2023 financial results. Revenue in the Q3 of 2023 was $223,000 which consisted of revenue from our platinum instrument and associated consumable kits. Gross profit was $108,000 Speaker 400:10:41and the Speaker 300:10:41gross margin was 48%. As I have stated before, our gross margin percentage will be somewhat variable for the near future as we work through our initial stages of commercialization and will also be impacted by the timing and mix of instruments versus consumable sales. GAAP total operating expenses in the Q3 of 2023 were $27,300,000 compared to 27,700,000 in the Q3 of 2022. Included within operating expenses are stock based compensation and restructuring charges. Removing these items, we arrive at an adjusted operating expenses, which were $23,900,000 for the Q3 of 2023 compared to $23,600,000 for the Q3 of 2022, reflecting an approximate $300,000 increase. Speaker 300:11:34What's important here is the details of the change. As a company, we have been able to maintain a minimal increase to our adjusted total operating expenses year over year for the quarter, while at the same time, we have ramped up our commercial operations team significantly. We have been able to do this based on our recent R and D realignment efforts as well as our disciplined efforts to utilize our capital in the most effective ways as possible. This is further displayed with our year over year adjusted total operating expenses. For the year to date period September 2023, adjusted total operating expenses is $72,600,000 compared to 77,900,000 for the same period in 2022, a $5,300,000 decrease. Speaker 300:12:21Though we are not committing to a particular operating expense spend level at this time, We are very aggressively looking at our spend to ensure maximum utilization of our capital to enhance and speed our R and D results, While ensuring that we have the resources to maximize our market penetration with our commercial team. Net loss for the Q3 of 2023 was $24,700,000 compared to $31,700,000 in the Q3 of 2022 and adjusted EBITDA for the Q3 of 2023 was negative $22,600,000 compared to negative $22,900,000 in the Q3 of 2022. As of September 30, 2023, we had $274,600,000 of cash, cash equivalents and investments in marketable securities. As we discussed today and previously, our guidance for the rest of 2023 includes our controlled commercial launch approach, while continuing to put in place significant building blocks from a commercial capability standpoint for execution for an anticipated full commercial launch in early 2024. Based on our R and D realignment progress and other initiatives, We expect our adjusted total operating expenses to be $100,000,000 for 2023 compared to $103,200,000 in 2022. Speaker 300:13:47We are still very confident that our existing cash, cash equivalents and investments in marketable securities will provide runway into 2026. Now I will turn the call back over to Jeff Hawkins for closing remarks. Speaker 200:14:03Thank you, Jeff. We have made significant progress during the last quarter led by the completion of our R and D strategic review. We are excited about the level of clarity and focus we achieved through this process, including the roadmap to deliver near and midterm product improvements, including our anticipated version 2 of our kits on track for launch in the Q1 of 2024. We are looking forward to providing additional updates on the version 2 will be participating in the next call. In the meantime, we are continuing to build our infrastructure to support our full commercial launch, are well adhering to our disciplined approach to capital deployment. Speaker 200:14:39Operator, please open the line for questions. Speaker 400:14:59Will be ready for questions. Operator00:15:01And your first question comes from the line of Kyle Mixon with Canaccord Genuity. Your line is now open. Speaker 400:15:09Hey, guys. Thanks for taking the questions. Jeff, I know you guys have this controlled launch ongoing and we shouldn't expect A huge uptick or bolus in placement anytime soon, I guess, and that makes sense, relatively appropriate given like the early stage of this launch. But it seems like a couple of placements again this quarter. How should we think about the placement and the shipment like trajectory kind of going forward? Speaker 400:15:36Is this controlled truly going to be kind of a couple of places each quarter or how should we start to think about it in the near term release and maybe going into 2024? Speaker 200:15:44Yes. Thanks for that question, Kyle. So I would say 2 things about it. I think we're in that controlled launch through the end of this year. As part of our preparation for a full launch early next year, we are initiating some commercial activities Both in terms of some hiring and potentially distribution related partners. Speaker 200:16:08So you may see a little uptick In the Q4 over what we've done the last couple of quarters, but not a sort of a significant rise. Really then the focus becomes the V2 kit launch in the Q1. And we really believe that's the catalyst. That kit in the hands of customers And seeing that increased performance become sort of the catalyst to be able to move to a full launch and start to see a scale up sort of quarter over quarter after that. Speaker 400:16:40Okay. All right. That was great. And then I guess most of the revenue right now is coming from instruments. That's probably some service revenue. Speaker 400:16:47That's relatively lower margin than consumables and this new kit sounds like that will help drive utilization next year and thereafter. But 45% and kind of like the high 40s, I think is what gross margin has been at thus far. Obviously pretty good for if your revenue base is instrument and service. So as you sort of roll out These improved kits and you have the utilization picking up with the expanding installed base. Could we see gross margin get above 50% next year at some point? Speaker 200:17:18Yes. Maybe I'll start and then I'll turn it over to Jeff for a few comments. The one thing I wanted to input here, Kyle, was As we've talked about on other calls, we did do a tremendous amount of value engineering when we built our machine. While we are selling an instrument in selling capital and there's sort of perceived margins of selling that, Obviously, at a much earlier stage, but maybe Jeff wants to comment a little bit on how we are thinking about that blend and sort of how it might change over the course of next year. Speaker 300:17:58Yes. I'll just add on saying that as we scale, we're going to have more opportunities to bring more and more of the kit manufacturing in house And have the ability to improve margins on that. Obviously, we need that scale to be able to achieve that improvement, But it's absolutely on our radar as we ramp up over the course of 2024 and beyond. Speaker 400:18:21Okay. That was great. That was great, guys. And Jeff Hawkins, is there anything you could kind of share with respect to the Almost like the backlog of customers and kind of like the leads that you've generated thus far and things like types of customers, The end markets, I know we talked about biotech before and maybe even like regions because there's a lot to think about when you think about the backlog and kind of pipeline. So it would be good to hear like what Be excited for going forward. Speaker 200:18:49Sure. Yes. The first thing I'd say Kyle is that the funnel tends to be sort of consistent with what we said in the in the quarter, it's heaviest in the U. S. Where we have our direct presence, still have a strong amount sort of similar levels to Q2 In terms of funnel in Europe, by coming out of the Hoopo World Congress, as we mentioned in our prepared remarks, Starting to get some of our first leads into the funnel for the Asia Pacific region. Speaker 200:19:20So I think as we get more visibility into Those other markets and interface with both customers and distributors will start to pick up in that regard. In terms of The split the academic market remains the biggest portion of our funnel. But as we said earlier in the year, we expected that Academic customers would represent those first customers in the majority of the funnel and then we would work and over time, We'd see it start to build in the pharma, biotech, and even government and industrial space. And I think that's what's transpiring. So the funnel continues to be over weighted to academic, but we are seeing more traction and we're getting sort of further into The funnel and the process with some of the pharma biotechs and government sort of accounts. Speaker 200:20:08So excited to see those types of customers Progressing, obviously, those types of customers can be very helpful in terms of your pull through And such, so excited about that trend as we look out to 2024. Speaker 400:20:25Okay. And then is anyone in the current installed base like a non beta user? Because I figure like most of these handful Of placements out there in the field are probably with those initial early access program users. And then with the funnel, I mean, that could be many potential placements over time. How many like new to QSI or new to, proteomics possibly customers does that represent? Speaker 200:20:51So our current installed base is Almost all are new to QSI. They were not necessarily part of the early access program. So the vast majority of those placements we've made throughout the year, Kyle, are net new to us in terms of not having been a part of the early access Program. Speaker 400:21:17Yes. Okay. That's great. That's great. Let me just ask another one, a last one before I hop off. Speaker 400:21:22On the pipeline and possibly the kits and everything, so you talked about how carbon is going to be, I guess, Discontinued, you're not going to be commercializing that anymore. In your explanation, it makes sense. I know it was touched on last quarter as well. And it sounds like that was kind In the cards, I guess, so it's not super surprising. As you look forward though, I mean, what type of hardware updates Or improvements do you sort of envision for Quantum SI? Speaker 400:21:47Like could there be a new box anytime soon? Is that necessary Maybe to get I feel like in Proteomics, there are some of these attributes and features that have to be kind of pretty robust and that does require I got a legitimate hardware type upgrade rather than just reagents, but that's one side of the question. The other is the version 2 kits and then we'll hear more about those. Is that mainly around Like increasing density of the chips or is this completely new, just chemistry based or something like that? Speaker 200:22:14Sure. Yes, let's take the 2 questions. So in terms of hardware versus kits, I would say that there's The existing platinum instrument and the existing 2 ms chip have a lot of headroom in terms of their capabilities and performance. The majority of what we need to do right now to unlock that is around a combination of the library prep, The sequencing reagent kit and even somewhat the surface chemistry of the chip that can influence things like loading. A lot of the focus is there. Speaker 200:22:51We certainly are working through our plans as it relates to what New types of hardware we might want to introduce over the coming years. We haven't really set a firm date on what the next platform would be, But we do see opportunities to continue to sort of grow the hardware portfolio to address other attributes that platform doesn't necessarily address today. I mean, in terms of the Version 2 kit, Kyle, the way I would think about it is We are touching upon improvements sort of across the set of kits that we sell to a customer. Everything from enhancements to the library prep kit and protocol, enhancements to the sequencing Reagents including the addition of a new recognizer for glutamic acid or E And just for your reference, right, that's the 3rd most abundant amino acid in the proteome. And then just overall increasing Through some improvements to surface chemistry, the sort of the amount of reads, the amount of output we're getting per run on the current chip. Speaker 200:24:02So, we expect to have more quantitative data to share when we get to the launch in the Q1 of next year. But Early data here internally in development, really market improvement over The current version of the chemistry and also seeing a lot lower sort of sample input requirement with the new library prep Sort of kit and protocol, which should help us really with that compatibility with the various sample prep kits and sample types. So we think that might improve Some of those interfaces with what the customer is trying to do upfront of our kits. Speaker 400:24:44Okay. Yes, sounds like a pretty solid and comprehensive update. I look forward to that. Thanks guys. Appreciate the time. Speaker 200:24:49Yes. Thank you, Kyle. Operator00:24:54One moment for the next question. And your next question comes from the line of Swayampakula Ramakanth with HCW. Your line is now open. Speaker 500:25:07Thank you. Good afternoon, Jeff and Jeff. Speaker 200:25:10Hi, Arnaud. Good afternoon. Operator00:25:14So Speaker 500:25:17You are planning to initiate the full launch early next year And at the same time also launch a second version of the kit. I'm just trying to understand Is there any reason for us to think one would happen before the other? Are they going to happen Together and are they dependent on each other in terms of deployment? I'm just trying to understand if there's What is the sequence of events that Reshinde is looking out for? Speaker 200:25:59Yes. RK, I would say that the working plan is that we would launch the V2 kit and then at Some period of time shortly after that, we would move to the full launch. I would not expect us to move to full launch in advance Of the V2 kit, we would sort of stay in the controlled launch we're in right now. So that's the way I would think about it as V2 kit And then somewhere between right after that to just shortly after that, we would move to the full launch. Speaker 500:26:31Okay. And what I don't I guess you'll discuss the V2 later. But in general terms, Is this going to be anything significantly different or in the sense that you need additional tweaking to the machine as it is now? Or do you you don't think there is something majorly different in the kit itself? Yes. Speaker 500:26:55So the machine Speaker 200:26:57is not impacted by this at all. The version 2 kits will be compatible with the existing platinum instrument that customers have. This is really improvements to a mix of either the library prep or sequencing reagents or an improvement we've made To the chip, we're not fundamentally changing the underlying 2 ms chip or the hardware itself. It's really this will be very seamless For customers, they'll receive the library prep and sequencing kits and run them with the same instrument and the same software they've been using It'd be a fairly seamless change for them. No sort of specific upgrades they need to go through. Speaker 500:27:36Okay. And then in terms of the data presentations or data publications that you're expecting this year and early next year. What sort of data should we be expecting from it? And then, would that data pretty much Portray what the current version of the instrument can deliver? Or is this going to be Something a little bit more than that in the sense so people like us can kind of think about, okay, what the next The version of the instrument itself could be and what better capabilities can be delivered? Speaker 200:28:20Sure. We talked about in the script the webinar and the presentation from Northwestern. That really represents the performance That customers are generating today with the existing instrument and the existing version of the chemistry. The publication that we discussed that we expect to be submitted before the end of the year, really showing some of the capabilities of the technology in the world of post translational modifications, but again using the existing kit and instrument. As we get into next year, I'd expect in the beginning of the year that any data that comes out would be generated with the kits that are in the market right now. Speaker 200:29:04And as the year progresses, more and more of that data coming out with the Version 2 kits. So there's always some lag between A version of chemistry and data that gets generated with that. But that's sort of how I would think about the near term versus midterm and throughout 2024. Speaker 500:29:23Okay, perfect. Yes. So basically those publications can certainly be used in marketing the products that are in the market right now. Speaker 200:29:32Yes, they could be used for that. We will obviously share internal data as part of our launch of the Version 2 kit to sort of prime But then turning immediately to working with some of these existing customers that have been part of the controlled launch Quickly implement the V2 in their laboratories and generate some data with that. So, you'll get a little bit more of a running start When you have an existing installed base, when you bring in an upgraded chemistry like we're going to do. Speaker 500:30:06Okay. And then you were talking about the ex U. S. Launch. With the way the launch is going here in the U. Speaker 500:30:16On a limited control basis, is the ex U. S. Launch It's going to be more like a typical launch or is that because it's going to be through a distributorship That it should be viewed a little bit different than what it is what is happening here in the United States. Speaker 200:30:42It's a good question, RK. So the way I think about it is, again, the Version 2 kit we think is really A key aspect of giving us the type of consistency of performance and capabilities that Make the implementation and adoption a sort of cycle with the customer as efficient as possible. That said, when we look at Europe, while we expect to have a small number of employees on the ground there to help support our activities. We do expect to use distributors in many markets. We haven't decided exactly Which markets, we may go direct in select markets, but I would expect us to use a reasonable number of countries being covered by distributors. Speaker 200:31:31I think our experience in markets like Europe would say that in the beginning, there'll be some Of that early market development, right, instrument being placed with the KOL, data being generated, being presented or At a major conference in the region, or being coming that sort of reference account and then you'll see sort of the sales pick up. So I don't expect The European launch to necessarily be in a defined sort of controlled launch. I would expect it to be more of a traditional launch, but with that initial Market development that exists when you place an instrument either directly or with a distributor in a new region of the world. Speaker 500:32:14Okay, Perfect. Thank you. Thank you for taking all my questions. Speaker 200:32:18You're welcome. Operator00:32:21And that is Speaker 200:32:29Thank you everyone for attending today. We look forward to providing you with more updates on our next call. Have a good evening.Read morePowered by